## **Core Concept**
Euvolemic hyponatremia in the context of congestive heart failure (CHF) often results from the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or from the use of certain medications. The management involves correcting the underlying cause and using specific treatments to increase serum sodium levels.

## **Why the Correct Answer is Right**
The correct answer, **Tolvaptan**, is a selective vasopressin V2 receptor antagonist. It works by increasing the excretion of free water without affecting electrolyte excretion, thereby increasing serum sodium levels. Tolvaptan is specifically indicated for the treatment of euvolemic and hypervolemic hyponatremia in patients with heart failure, cirrhosis, and SIADH.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because the drug listed is not recognized as a treatment for euvolemic hyponatremia in CHF.
- **Option B:** This option is incorrect as the listed drug does not match the pharmacological action required for treating euvolemic hyponatremia in CHF.
- **Option C:** This option might seem plausible but is incorrect because, although diuretics can be used in managing fluid overload states, they are not the specific treatment for euvolemic hyponatremia.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Tolvaptan** is a specific and effective treatment for euvolemic hyponatremia, particularly in patients with CHF. It is crucial to distinguish between euvolemic and hypervolemic hyponatremia, as treatments may vary. Tolvaptan's role in managing euvolemic hyponatremia in CHF patients is well established.

## **Correct Answer:** D. Tolvaptan.